Breaking News Instant updates and real-time market news.

CMCSA

Comcast

$37.91

0.1 (0.26%)

, DIS

Disney

$110.72

-0.9 (-0.81%)

09:09
09/24/18
09/24
09:09
09/24/18
09:09

Fly Intel: Pre-market Movers

HIGHER: Disney (DIS), up 1% after Bernstein analyst Todd Juenger says this weekend's outcome of the bidding war for Sky (SKYAY) was "the best possible result" for the company. Class A shares of Fox (FOXA) are also up about 1% following the news... Amarin (AMRN), up 280% after the REDUCE-IT study met its primary endpoint... Epizyme (EPZM), up 18% after announcing the FDA has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials... Pandora (P), up 7.5% after announcing a definitive agreement under which SiriusXM (SIRI) will acquire Pandora in an all-stock transaction valued at approximately $3.5B... Rangold (GOLD), up 7% after Barrick (ABX) agreed to acquire the company in all-stock deal... Intrexon (XON), up 13% after announcing advances in production of medical cannabis. LOWER: Nutanix (NTNX), down 9% after filing to sell 2.45M shares of common stock for holders and seeing its stock downgraded to Negative from Neutral at Susquehanna... Bilibili (BILI), down 6% after Morgan Stanley analyst Alex Poon downgraded the stock to Equal Weight from Overweight, telling investors that he thinks the company's transformation from a game-centric company to a profitable social platform is still in its early stages... AnaptysBio (ANAB), down 3% after announcing topline proof-of-concept data for etokimab, its investigational anti-IL-33 therapeutic antibody... Comcast (CMCSA), down 4.5% after announcing that it has prevailed with the highest offer price in the auction to acquire the entire issued and to be issued share capital of Sky with an offer price of GBP17.28 per share.

CMCSA

Comcast

$37.91

0.1 (0.26%)

DIS

Disney

$110.72

-0.9 (-0.81%)

FOXA

21st Century Fox

$44.33

-0.26 (-0.58%)

AMRN

Amarin

$3.00

0.06 (2.04%)

EPZM

Epizyme

$10.30

-0.1 (-0.96%)

P

Pandora

$9.08

-0.31 (-3.30%)

SIRI

Sirius XM

$6.97

-0.05 (-0.71%)

GOLD

Randgold

$63.94

-0.64 (-0.99%)

ABX

Barrick Gold

$10.48

-0.135 (-1.27%)

XON

Intrexon

$14.50

-0.035 (-0.24%)

NTNX

Nutanix

$46.55

-1.43 (-2.98%)

BILI

Bilibili

$12.47

-0.93 (-6.94%)

ANAB

AnaptysBio

$92.83

0.61 (0.66%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$43.97

-0.23 (-0.52%)

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 27

    Sep

  • 01

    Oct

  • 02

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 29

    Oct

  • 10

    Dec

CMCSA Comcast
$37.91

0.1 (0.26%)

09/24/18
OPCO
09/24/18
DOWNGRADE
OPCO
Perform
Oppenheimer downgrades Comcast to Perform following Sky acquisition
Oppenheimer analyst Timothy Horan downgraded Comcast (CMCSA) to Perform from Outperform and removed his $42 price target after the company won the auction for Sky (SKYAY). Comcast is acquiring Sky for 14 times EBITDA, or double its own multiple, Horan tells investors in a research note. The analyst expects Comcast to use Sky's over-the-top platforms and see good cross-selling opportunities. However, he believes Comcast needs to invest in U.S. wireless and over-the-top capabilities and "ultimately consolidate" the U.S. cable industry in order to "protect its franchise here." He sees increased competitive pressures for Comcast from new technologies.
09/24/18
MOFT
09/24/18
DOWNGRADE
MOFT
Neutral
Comcast downgraded to Neutral from Buy at MoffettNathanson
09/24/18
LOOP
09/24/18
NO CHANGE
Target $51
LOOP
Buy
21st Century Fox favored over Disney on on Comcast-Sky deal, says Loop Capital
Loop Capital analyst Alan Gould kept his Buy rating and $51 price target on 21st Century Fox (FOXA), saying that while Disney (DIS) should also rise on the latest news of Comcast (CMCSA) buy Sky (SKYAY), "asymmetrical returns" favor Fox as Disney stock price "approaches the high end of the collared range for the Fox transaction". The analyst notes that he is positive on Fox "as an attractive way to buy Disney and create shares in the spinoff New Fox". Gould adds that while missing on Sky "complicates Disney's direct-to-consumer" Europe strategy, he believes investors will reward its stronger balance sheet and its independent efforts of launching a global streaming business.
09/24/18
BERN
09/24/18
NO CHANGE
BERN
Sky's bidding war outcome 'best possible result' for Disney, says Bernstein
Bernstein analyst Todd Juenger says this weekend's outcome of the bidding war for Sky (SKYAY) was "the best possible result" for Disney (DIS). The analyst argues that he never understood why Disney would want to operate a European DBS business, and never understood how Sky would contribute to Disney's DTC strategy. Rather than pay such a premium like Comcast (CMCSA), Disney can now get "paid" that premium, assuming Fox (FOXA) agrees to sell and deliver the proceeds to Disney in lieu of the shares they had promised, the analyst contends.
DIS Disney
$110.72

-0.9 (-0.81%)

09/19/18
UBSW
09/19/18
DOWNGRADE
UBSW
Neutral
Sky downgraded to Neutral from Buy at UBS
UBS downgraded Sky (SKYAY) to Neutral while raising its price target for the shares to 1,600p from 1,500p. The firm cites valuation for the downgrade with the stock up over 70% in the last 12 months. Sky shares are pricing in high probability that Disney (DIS)/Fox (FOXA) will return with a higher offer, UBS says. It continues to believe the company is "strategically valuable" to both Disney/Fox and Comcast (CMCSA).
09/18/18
LOOP
09/18/18
NO CHANGE
Target $125
LOOP
Buy
Disney expected to acquire Sky through Fox, says Loop Capital
Loop Capital analyst Alan Gould kept his Buy rating and $125 price target on Disney (DIS), saying he continues to expect the company to acquire Sky (SKYAY) through Fox (FOXA) ahead of the 5-day auction process that may begin next week. The analyst believes that Disney "can afford to overpay" for the assets that he deems to be "strategically important" to its global DTC business and expects Fox to raise its Sky bid to "at least" match the GBP14.75 per share offer from Comcast (CMCSA). Gould also raises his expected Disney FY18 EPS view by 2c to $6.95 to account for strong film results in the current quarter.
FOXA 21st Century Fox
$44.33

-0.26 (-0.58%)

AMRN Amarin
$3.00

0.06 (2.04%)

08/02/18
HCWC
08/02/18
NO CHANGE
Target $10
HCWC
Buy
Amarin risk/reward favorable into Reduce-It data, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein views the risk/reward profile on Amarin shares as "highly favorable" into the Reduce-It trial readout this September. The full value of Amarin resides with a successful trial outcome, Fein tells investors in a research note. He says he can "easily justify" a $14 price target with a 100% probability of success for the trial, representing 450% upside. If the trial is a miss, Fein says his price target would be $2, implying "only" 30% downside. He believes Vascepa may become the standard of care following Reduce-It outcome. The analyst keeps a Buy rating on Amarin with a $10 price target.
07/19/18
CANT
07/19/18
NO CHANGE
Target $10
CANT
Overweight
Amarin's Vascepa remains underappreciated, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen points out that Amarin's Reduce-It trial was highlighted in a Journal of the American review article titled "Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management." The analyst believes this supports her view that the market opportunity for Vascepa is still underappreciated. The paper highlights the unmet need for addressing residual risk for major adverse cardiovascular events even after intensive statin therapy, Chen tells investors in a research note. The analyst keeps an Overweight rating on Amarin shares with a $10 price target.
08/27/18
CANT
08/27/18
NO CHANGE
Target $10
CANT
Overweight
Ascend trial outcome does not mean Amarin study will fail, says Cantor
Cantor Fitzgerald analyst Louise Chen says that as expected, the omega-3 arms of the Ascend trial, sponsored by Oxford University and British Heart Foundation, did not demonstrate a reduction of first serious vascular events with the therapy of omega-3 fatty acid supplementation studied. The analyst does not think this means that Amarin's Reduce-It study will not show a benefit for patients. Because Ascend was expected to be negative, an overhang has now been removed ahead of the Reduce-It readout, Chen tells investors in a research note. She thinks now is a good time to take another look at Amarin shares given the upcoming potential catalyst. Chen has an Overweight rating on Amarin with a $10 price target. This post corrects the headline as the Ascend study was not run by Amarin as previously stated.
08/06/18
CANT
08/06/18
NO CHANGE
Target $10
CANT
Overweight
Amarin risk/reward favorable ahead of Q3 data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen views the risk/reward for Amarin shares as favorable ahead of what she expects will be positive results for its Reduce-It outcomes study. Positive results from the study, which are expected by the end of Q3, should drive upward earnings revisions to levels not reflected in consensus numbers and the stock higher, Chen tells investors in a research note. The Street thinks Reduce-It will fail, the analyst adds. She affirms an Overweight rating on Amarin with a $10 price target.
EPZM Epizyme
$10.30

-0.1 (-0.96%)

08/03/18
JEFF
08/03/18
NO CHANGE
Target $22
JEFF
Buy
Epizyme looks oversold after yesterday's pullback, says Jefferies
Jefferies analyst Michael Yee attributes the selloff yesterday in shares of Epizyme to the delay and push-out of the new drug application to the first half of 2019 and uncertainty around the partial clinical hold. The stock is becoming more of a "2019 play" for the NDA filing and full EZH2 data, Yee tells investors in a research note. Over the short term, the analyst views the stock as oversold and thinks it will bounce back on removing the clinical hold over the next two months. Yee keeps a Buy rating on Epizyme and lowered his price target for the shares to $22 from $27.
09/21/18
SBSH
09/21/18
NO CHANGE
SBSH
Buy
Citi opens 30 day catalyst watch for Epizyme
Citi analyst Robyn Karnauskas opened a 30 day catalyst watch for Epizyme in anticipation of an FDA decision on the partial hold on Tazemetostat. In the best case scenario, the analyst expects the partial hold to be lifted at the end of the 30 day period without any further delay. She notes that We note that Tazemetostat has been investigated in multiple indications, administered to 750 patients, and shown an overall positive safety profile with only a single case of secondary lymphoma. The analyst keeps a Buy rating on Epizyme.
09/07/18
MSCO
09/07/18
INITIATION
Target $12
MSCO
Equal Weight
Epizyme resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst David Lebowitz resumed coverage of Epizyme with an Equal Weight rating and $12 price target, recommending investors stay on the sidelines despite tazemetostat's potential as the partial clinical hold imposed in April by the FDA clouds the timing and increases the level of risk for the drug.
07/03/18
LEER
07/03/18
DOWNGRADE
LEER
Market Perform
Epizyme downgraded to Market Perform from Outperform at Leerink
P Pandora
$9.08

-0.31 (-3.30%)

08/01/18
08/01/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AutoZone (AZO) upgraded to Buy from Hold at Deutsche Bank with analyst Mike Baker saying Improving comps and fundamentals, coupled with a stock that has underperformed year-to-date, has brought a "compelling" valuation. 2. Pandora (P) upgraded to Outperform from Sector Perform at RBC Capital with analyst Mark Mahaney saying the company's double-digit organic revenue growth and declining EBITDA losses were driven by improving execution, adding that while the 2% active listener hours decline is a worry, the valuation on the stock is "undemanding" given its expected annualized revenue growth of about 10% over the next 3 years. 3. Papa John's (PZZA) upgraded to Buy from Hold at Jefferies with analyst Alexander Slagle saying the stock, down 50% from highs, now reflects the likelihood that fundamentals will get worse before improving. 4. Electronic Arts (EA) upgraded to Buy from Hold at Argus with analyst Joseph Bonner saying the latest pullback in the stock price after the company's recent Q1 earnings report offers a favorable entry point. 5. Sarepta (SRPT) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Matthew Harrison saying the stock is down about 34% since June 19 after having moved up by about 50% when its initial DMD gene therapy data was announced. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/02/18
MKMP
08/02/18
NO CHANGE
Target $8
MKMP
Neutral
Pandora price target raised to $8 at MKM Partners
MKM Partners analyst Rob Sanderson raised his price target on Pandora to $8 from $6.25 after its "modestly better than consensus" Q2 EBITDA loss and a revenue beat. The analyst keeps also his Neutral rating, noting that the company's user base continues to decline. Sanderson adds that there is little visibility into Pandora's outlook regarding subscription vs. ad-supported revenue mix, the impact of "marketing reallocation" with respect to its user growth, and the uncertainties around cost of content and minimum guarantees.
08/27/18
BMOC
08/27/18
NO CHANGE
Target $13
BMOC
Outperform
Pandora's 'self-serve platform' to be its next growth driver, says BMO Capital
BMO Capital analyst Daniel Salmon kept his Outperform rating and $13 price target on Pandora after his recent investor meeting with the company CFO and investor relations team. The analyst notes that he now has a "more robust" view of Pandora's vision of digital audio advertising platform, adding that the company's "next legs" of growth will come from a "self- serve platform" offering access to both Pandora and third party inventory. Salmon further cites the company's "new approach to podcast advertising that leverages data-driven targeting" and moves away from "host-read promotions".
09/12/18
NEED
09/12/18
NO CHANGE
Target $13
NEED
Buy
Pandora price target raised to $13 from $8 at Needham
Needham analyst Laura Martin raised her price target on Pandora to $13 and kept her Buy rating after meeting with its management. Based on the discussions, the analyst expects the company to drive upside to value through accelerated subscriber growth from its partnership focus and also derive revenue upside from podcasts and other non-music content. Martin also anticipates better relationships with music labels to help Pandora "lower minimum guarantee payments" as well as generate cost efficiencies.
SIRI Sirius XM
$6.97

-0.05 (-0.71%)

07/30/18
SPHN
07/30/18
NO CHANGE
Target $60
SPHN
Overweight
Live Nation price target raised to $60 from $50 at Stephens
Stephens analyst Kyle Evans said he expects solid results from Live Nation (LYV) for the rest of 2018 and sees few fundamental risks. However, he notes he is becoming "increasingly valuation sensitive" given the recent 35% run-up in the stock, which he attributes to its solid results, suspicion that the company is "intentionally under-earning" and new speculation that the company could be acquired by Sirius XM (SIRI). Evans keeps an Overweight rating on Live Nation with an increased price target of $60.
07/24/18
BTIG
07/24/18
UPGRADE
Target $60
BTIG
Buy
Live Nation upgraded to Buy at BTIG on outperforming growth and M&A
As reported earlier, BTIG analyst Brandon Ross upgraded Live Nation (LYV) to Buy from Neutral with a $60 price target, saying he is now more convinced that the company will outperform expectations amid inflecting growth rate with an added possibility of M&A. Despite the tough comparisons, Ross notes that Live Nation should "handily" top operating income consensus in FY18 and going forward, having build an "insurmountable" competitive float in U.S. markets, and that its mid-teens EBITDA growth is "the new normal". The analyst further believes that a near-term combination between Live Nation and Sirius XM (SIRI) is "inevitable".
07/10/18
FBCO
07/10/18
INITIATION
Target $8.5
FBCO
Outperform
Sirius XM initiated with an Outperform at Credit Suisse
Credit Suisse analyst Doug Mitchelson initiated Sirius XM with an Outperform and $8.50 price target saying there are no negative catalysts on the horizon and expects a "powerful" buyback will drive valuation higher.
06/29/18
06/29/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. KB Home (KBH) upgraded to Buy from Underperform at BofA/Merrill with analyst John Lovallo saying KB Home's execution, margins and returns have exceeded his expectations for numerous quarters and expects solid homebuilding growth through 2020. 2. Sirius XM (SIRI) upgraded to Outperform from Market Perform at Barrington with analyst James Goss stating he is impressed with the longer-term story Sirius continues to offer and considers the recent downward move in the stock price as providing a buying opportunity. 3. Matador (MTDR) upgraded to Buy from Hold at KLR Group with analyst Gail Nicholson saying the company offers investors "solid" execution, a "strong" balance sheet and numerous catalysts which could unlock incremental value. 4. Duluth Holdings (DLTH) upgraded to Outperform from Market Perform at William Blair with analyst Dylan Carden stating he has greater conference that the direct channel will stabilize and even likely accelerate as new retail markets enter their second year. 5. American Express (AXP) upgraded to Buy from Neutral at Buckingham with analyst Chris Brendler citing the DOJ case being resolved and evidence of "compelling momentum" across its platform. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GOLD Randgold
$63.94

-0.64 (-0.99%)

08/17/18
DESJ
08/17/18
UPGRADE
DESJ
Buy
Randgold upgraded to Buy from Hold at Desjardins
06/08/18
JPMS
06/08/18
UPGRADE
Target $94
JPMS
Overweight
Randgold upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Dominic O'Kane upgraded Randgold to Overweight citing valuation with the shares down 15% year-to-date. The analyst lowered his price target for the shares to $94 from $98.
08/29/18
UBSW
08/29/18
UPGRADE
UBSW
Buy
Randgold upgraded to Buy from Neutral at UBS
UBS analyst Daniel Major upgraded Randgold Resources to Buy with a price target of 6,000p. After underperforming in the 2018, the shares offer an attractive risk/reward profile, Major tells investors in a research note. The analyst sees the company meeting its guidance and anticipates its excess cash will be returned to shareholders. He also believes risks to gold prices are skewed to the upside.
04/04/18
RBCM
04/04/18
DOWNGRADE
RBCM
Underperform
Randgold downgraded to Underperform from Sector Perform at RBC Capital
RBC Capital analyst Tyler Broda downgraded Randgold to Underperform from Sector Perform and lowered his price target to GBp4,900 from GBp6,200. Broda notes that while Randgold has some positives such as a strong balance sheet, a high dividend and a disciplined track record on acquisitions, its attributable production has reached peak levels as its Tongon site is reaching the end of its life and growth from Massawa is uncertain. The analyst further attributes his rating revision to enhanced operating risks in Africa and the uncertainty around the cash flows from the Kibali mine in the Congo.
ABX Barrick Gold
$10.48

-0.135 (-1.27%)

08/28/18
SBSH
08/28/18
UPGRADE
Target $11
SBSH
Neutral
Barrick Gold upgraded to Neutral from Sell at Citi
Citi analyst Alexander Hacking upgraded Barrick Gold (ABX) to Neutral from Sell but lowered his price target to $11 from $12 as part of his broader research note on North American gold miners. The analyst states that he is still neutral on the sector, even though the risk for the price of gold is now "skewed to the upside", adding that he still prefers copper miners based on their superior growth to free cash flow profile. Hacking states that Barrick Gold is particularly compelling, with the stock price having fallen about 30% and sees little support for the bear case with gold price close to $1,200/oz, adding that the stock may be nearing a bottom and has a potential to outperform if it can "rebuild" investor trust with execution. As part of his research note, the analyst also lowers his price target on Agnico Eagle (AEM) to $38 from $45, Goldcorp (GG) to $14 from $16, and Newmont Mining to $36 from $42.
08/28/18
SBSH
08/28/18
UPGRADE
SBSH
Neutral
Barrick Gold upgraded to Neutral from Sell at Citi
08/06/18
JEFF
08/06/18
DOWNGRADE
Target $11
JEFF
Hold
Barrick Gold downgraded to Hold from Buy at Jefferies
Jefferies analyst Christopher Lafemina downgraded Barrick Gold to Hold and lowered his price target for the shares to $11 from $17. The analyst remains cautious on North America gold miners and sees continuing uncertainty at Acacia for Barrick. Further, he has concerns over the company's strategic direction following the departure of president Kelvin Dushnisky.
07/30/18
RBCM
07/30/18
DOWNGRADE
Target $14
RBCM
Sector Perform
Barrick Gold downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Stephen Walker downgraded Barrick Gold to Sector Perform from Outperform and lowered his price target to $14 from $16. The analyst cites increased uncertainty and a more cautious outlook as a result of the company's strategy shifts, but also notes that those headwinds are reflected in the current share price.
XON Intrexon
$14.50

-0.035 (-0.24%)

07/16/18
07/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aptinyx (APTX) initiated with an Overweight at JPMorgan and an Outperform at BMO Capital as well as Aptinyx (APTX). 2. Magenta Therapeutics (MGTA) initiated with an Outperform at Wedbush, an Outperform at Cowen and JPMorgan, as well as a Buy at Goldman Sachs. 3. Wyndham Destinations (WYND) and Marriott Vacations (VAC) were initiated with a Buy at Jefferies while Hilton Grand Vacations (HGV) was initiated with a Hold. 4. AvroBio (AVRO) initiated with an Outperform at Wedbush, Cowen, and Wells Fargo, and an Overweight at Morgan Stanley. 5. Keurig Dr Pepper (KDP) resumed with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/16/18
BOFA
07/16/18
DOWNGRADE
BOFA
Underperform
Intrexon downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Derik de Bruin downgraded Intrexon to Underperform and cut its price target to $12 from $19 given lack of near-term catalysts and lack of contribution from "advanced" programs until 2020s. The analyst notes the Okanagan Apples business is only expected to have $20M in 2020 sales and other programs have yet to contribute meaningful revenues.
11/10/17
STFL
11/10/17
NO CHANGE
Target $39
STFL
Buy
Intrexon price target lowered to $39 from $57 at Stifel
Stifel analyst Thomas Shrader lowered his price target on Intrexon to $39 from $57 citing "multiple issues," including longer than expected development times for its energy program and increased competitive pressure in gene therapy. However, he keeps a Buy rating on the shares, saying the company's call "seemed very positive," and noting management's increased focus on crop protection and away from mosquitos.
07/16/18
07/16/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Netflix (NFLX) downgraded to Underperform from Neutral at Buckingham with analyst Matthew Harrigan saying he estimates that the stock's current price implies "optimistic" views of the company reaching 360M global members in 2025 and 505M by 2033 along with a long-term operating profit margin near 35%. 2. Rockwell Automation (ROK) downgraded to Sell from Neutral at Goldman Sachs while Parker-Hannifin (PH) was downgraded to Neutral from Buy. 3. FedEx (FDX) downgraded to Neutral from Buy at UBS with analyst Thomas Wadewitz saying with a large global Express business representing 55% of revenue and about 13% of revenue linked to Asia, FedEx is exposed to risk from tariffs and potentially slower trade activity. 4. Hasbro (HAS) downgraded to Underperform from Market Perform at BMO Capital with analyst Gerrick Johnson saying the liquidation of Toys R US may be "more impactful than investors realize" after the initial 9% rally in the stock price on "relief that things were not worse," even as retailers are becoming more selective in the "pantry loading" inventory restocking process. 5. Intrexon (XON) downgraded to Underperform from Neutral at BofA/Merrill with analyst Derik de Bruin citing lack of near-term catalysts and lack of contribution from "advanced" programs until 2020s. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NTNX Nutanix
$46.55

-1.43 (-2.98%)

09/18/18
09/18/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JPMORGAN CUTS ESTIMATES, PRICE TARGET ON FACEBOOK: JPMorgan analyst Doug Anmuth lowered his 2019 and 2020 earnings estimates for Facebook (FB) by 5%-6% on the company's bigger investment increases over the next couple years, which he does not believe are fully captured in consensus estimates. Even with Facebook suggesting it could reach mid-30% operating margins in a few or several years, investments in 2019 could be larger than anticipated in consensus estimates, Anmuth said. The analyst also cut his price target for the shares to $195 from $205. However, he kept an Overweight rating on Facebook. PIVOTAL CUTS DISCOVERY TO SELL: Pivotal Research analyst Brian Wieser downgraded Discovery (DISCA) to Sell with an unchanged price target of $26. Despite "tepid" earnings and "underwhelming" longer-term trends, the stock is up 20% over the past month, Wieser noted. While Discovery's agreements with Hulu and Sling are positive, they do not meaningfully alter the company's fundamentals, the analyst added. His price target implies 19% downside from current share levels. MIZUHO BOOSTS AMD PRICE TARGET: Mizuho analyst Vijay Rakesh raised his price target for AMD (AMD) to $36 from $20 after meeting PC supply chain companies in Asia. AMD's expected server EPYC shipment spike in Q4 will be key, as Intel (INTC) continues to lack a CEO and a competitive technology response to AMD's 12nm Ryzen and 7nm Vega launch, Rakesh said. The analyst, who admits there could be "near-term bumps," kept a Buy rating on shares of AMD. CANACCORD SAYS KAPERNICK AD HAS 'OVERWHELMING' SUPPORT: Canaccord analyst Camilo Lyon conducted a proprietary survey to assess the impact of Nike's (NKE) "Just Do It" ad featuring former NFL quarterback Colin Kapernick. The findings suggest the impact was overall positive and he expects the company to confirm that when it reports Q1 results next week. He believes the ad has had the intended effect of positively skewing the company's brand perception and likely provided a bump in sales. Lyon reiterated his Buy rating and $95 price target on Nike shares. PIPER, WILLIAM BLAIR DEFEND NUTANIX: Nutanix (NTNX) shares dropped 11.5% Monday due to an article from The Information citing a potential competitive hyperconverged infrastructure offering from Google (GOOG, GOOGL), but Piper Jaffray analyst Andrew Nowinski views the selling pressure as "excessive" and reiterates an Overweight rating on Nutanix with a $66 price target. William Blair analyst Jason Ader called the fear of competition from Google "overblown" and reiterated an Outperform rating on Nutanix.
09/24/18
SUSQ
09/24/18
DOWNGRADE
SUSQ
Negative
Nutanix downgraded to Negative from Neutral at Susquehanna
09/18/18
WBLR
09/18/18
NO CHANGE
WBLR
Outperform
Fears of Google competition for Nutanix look overblown, says William Blair
Shares of Nutanix (NTNX) fell yesterday after The Information reported that Google (GOOG, GOOGL) is working on a potential hyperconverged infrastructure product that could conceptually compete with Nutanix, William Blair analyst Jason Ader tells investors in a research note titled "Fears of Google Entering HCI Space Look Overblown to Us". This is likely Google's response to what Microsoft (MSFT) has built with Azure Stack, which is Microsoft's HCI product that connects directly into its Azure public cloud service, Ader contends. He believes that if Google turn this into an actual packaged HCI product sold to a broad range of customers, it could create longer-term risk for Nutanix. However, thinks investors should consider that this appears to be another validation of the staying power of the on-premises market, which he says bodes well for Nutanix. Further, he points out that if Google were to decide to enter the HCI market more broadly, it would have a long way to go to establish itself in the enterprise against entrenched players like Nutanix and VMware (VMW). Google has not had great success selling into the enterprise historically and has little experience selling enterprise infrastructure appliances, Ader writes. The analyst reiterates an Outperform rating on Nutanix.
09/21/18
OPCO
09/21/18
NO CHANGE
Target $70
OPCO
Outperform
Buy the weakness at Nutanix, says Oppenheimer
Oppenheimer analyst Ittai Kidron reiterates an Outperform rating and $70 price target on Nutanix (NTNX), telling investors in a research note to buy the weakness. Kidron says he came away from recent meetings with management confident in the company's opportunity, strategy, execution, and competitive position. Takeaways from the meetings include that Google (GOOG, GOOGL) is not likely to compete with Nutanix, and that opex investment is likely to remain high, but balanced against sales productivity and free cash flow.
BILI Bilibili
$12.47

-0.93 (-6.94%)

05/07/18
JPMS
05/07/18
INITIATION
Target $14
JPMS
Overweight
Bilibili initiated with an Overweight at JPMorgan
JPMorgan analyst Alex Yao started Bilibili with an Overweight rating and $14 price target. The company is an "undisputed vertical leader" among video content platforms targeting Generation Z, with "unique social features and rich content library" in animation, comics and gaming, Yao tells investors in a research note. He believes Bilibili's "multifaceted" revenue models are at the early development stage.
05/07/18
05/07/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with an Outperform at Telsey Advisory. 2. Zuora (ZUO) initiated with a Buy at Needham and Jefferies, an Equal Weight at Morgan Stanley, and a Neutral at Goldman Sachs. 3. Bilibili (BILI) initiated with an Overweight at JPMorgan. 4. Cloudera (CLDR) initiated with a Buy at Craig-Hallum. 5. Scynexis (SCYX) assumed with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/24/18
09/24/18
DOWNGRADE
Target $11

Equal Weight
Morgan Stanley downgrades Bilibili to Equal Weight after pushing out profit view
As previously reported, Morgan Stanley analyst Alex Poon downgraded Bilibili to Equal Weight from Overweight, telling investors that he thinks the company's transformation from a game-centric company to a profitable social platform is still in its early stages. Given that its investments are outpacing revenue growth, Poon does not expect operating profit to turn positive until 2020, he stated. While he remains positive on the long-term story, the valuation of Bilibili shares "appears full," added Poon, who lowered his price target on the stock to $11 from $13.50.
09/24/18
MSCO
09/24/18
DOWNGRADE
MSCO
Equal Weight
Bilibili downgraded to Equal Weight from Overweight at Morgan Stanley
ANAB AnaptysBio
$92.83

0.61 (0.66%)

09/13/18
STFL
09/13/18
INITIATION
Target $127
STFL
Buy
AnaptysBio resumed with a Buy at Stifel
Stifel analyst Derek Archila resumed coverage of AnaptysBio (ANAB) with a Buy rating and $127 price target, stating that he is positively biased heading into etokimab's Phase 2a results for severe eosinophilic asthma, given his view on the strong rationale for the inhibition of IL-33, etokimab's meaningful reduction of eosinophils seen in an earlier Phase 2a study, and the success of Regeneron (REGN) and Sanofi's (SNY) Dupixent.
08/28/18
08/28/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. II-VI (IIVI) initiated with a Buy at Deutsche Bank while Cree (CREE) was initiated with a Hold. 2. Arlo Technologies (ARLO) initiated with an Outperform at Imperial Capital and Cowen, a Buy at Deutsche Bank, a Neutral at BofA/Merrill and Guggenheim, as well as a Market Perform at Raymond James. 3. AnaptysBio (ANAB) initiated with an Overweight at Cantor Fitzgerald. 4. Oshkosh (OSK) initiated with a Neutral at Buckingham. 5. nLight (LASR) initiated with a Sell at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/17/18
CANT
09/17/18
NO CHANGE
Target $124
CANT
Overweight
Data on IL36R inhibitor positive for AnaptysBio, says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle views the first clinical data of an IL36R inhibitor in patients presented at EADV Congress as a positive read-through to AnaptysBio's IL36R program. Anaptys's second wholly owned clinical stage asset, ANB019, is an IL36R inhibitor in development for rare forms of psoriasis, Merle tells investors in a research note. She points out that data over the weekend from a competitor program, BI 655130, showed that IL36R inhibition can lead to clinically meaningful improvement in generalized pustular psoriasis. The analyst thinks this de-risks the IL36R mechanism ahead of initial patient data from ANB019 in GPP in early 2019. Merle keeps an Overweight rating on AnaptysBio with a $124 price target
09/04/18
CANT
09/04/18
NO CHANGE
Target $124
CANT
Overweight
AnaptysBio second clinical program could bring upside, says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle, who initiated coverage of AnaptysBio last week with an Overweight rating and $124 price target, thinks overall sentiment on the name is positive ahead of the asthma data in Q3. However, she gets the sense that some investors are on the sidelines, viewing the asthma data as a de-risking event. Awareness in AnaptysBio's second clinical program, ANB-019, remains low, Merle tells investors in a research note. She thinks this supports her thesis that the program could be an "underappreciated upside driver."
CMCSK Comcast
$0.00

(0.00%)

07/25/18
JPMS
07/25/18
NO CHANGE
JPMS
Overweight
Invalidated patent 'not material' to TiVo court fight, says JPMorgan
JPMorgan analyst Sterling Auty noted that the USPTO's Patent Trial and Appeal Board has declared patent 8,433,696 held by TiVo (TIVO) to be invalid as it believes that the technology involves a variation of earlier know-how. While a "scary headline," the reality is this does not matter in terms of TiVo's court case with Comcast (CMCSA), since this patent was dropped from the case, said Auty, who keeps an Overweight rating on TiVo shares.
07/13/18
BERN
07/13/18
NO CHANGE
BERN
Bernstein 'not so sure' Comcast will give up on Fox assets
Bernstein analyst Todd Juenger said that it appears that the market is starting to believe Comcast (CMCSA) will give up on its bid to buy assets from 21st Century Fox (FOXA) and focus on Sky (SKYAY), but he said he is "not so sure" that is the case after only one counter from Disney (DIS). He does not believe Comcast would put forth a $35 bid unless it was prepared to bid up to near $45 per share, Juenger tells investors. If Comcast ups its bid, it either wins Fox at a high price or Disney is forced to pay more, which both seem better than giving up to him, Juenger stated. In any case, the "winner" will be left with increased leverage on a cyclical business late in the cycle at a time when it needs to invest significantly to build its direct-to-consumer business, added Juenger.
07/13/18
07/13/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. VF CORP DOUBLE UPGRADE: BofA Merrill Lynch analyst Robert Ohmes upgraded VF Corp (VFC) to Buy from Underperform and raised his price objective to $96 from $65 ahead of the company's earnings report on July 20, telling investors in a research note that he believes Vans will be a "go-to-brand" for the back-to-school selling season. He said his channel checks indicate accelerating momentum in Vans, especially classic styles, and that the $50-$60 price point is attractive given consumers' shift to value. RAYMOND JAMES DOWNGRADES AT&T: Raymond James downgraded AT&T (T) to Market Perform from Outperform. Analyst Frank Louthan said he views the Department of Justice appeal of the Time Warner case as a negative and said it is a "frustrating delay." Louthan expects the suit to be a "significant overhang" for an extended period of time, which will limit share appreciation, but remains confident AT&T will prevail. AT&T is lower by 2% in late morning trading. STIFEL STARTS GALMED WITH A BUY: Stifel analyst Adam Walsh initiated Galmed (GLMD) with a Buy rating and $35 price target, calling it a "legitimate late-stage NASH play" after Aramchol recently proved itself in a Phase 2 trial as a clearly active and "very safe" compound for treating NASH. Galmed is trading higher by over 17% in late morning trading. MORGAN STANLEY HIKES WWE TARGET TO $100: Morgan Stanley analyst Benjamin Swinburne said that WWE (WWE), by securing rights fees in its new five-year agreements with NBC (CMCSA, CMCSK) and Fox (FOX, FOXA) that are 3.6 times higher than its prior five-year broadcast agreement with NBC, has gained a "massive increase" in earnings power and "extremely high" visibility into the associated revenue. Given the recently announced deals, he raised his price target on WWE shares to $100 from $58 and kept an Overweight rating on the stock. WILLIAM BLAIR CALLS KEMPER PULLBACK 'BUYING OPPORTUNITY': William Blair analyst Adam Klauber said he views shares of Kemper (KMPR) as "even more attractive" after the recent pullback, which he attributes to selling pressures from Infinity Property shareholders receiving Kemper stock. Klauber said Kemper "continues to be our top conviction idea," and kept an Outpeform rating on the name. Kemper is higher by 4.8% in late morning trading.
FOX 21st Century Fox
$43.97

-0.23 (-0.52%)

08/09/18
08/09/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GOLDMAN CUTS SEAGATE TO SELL: Goldman Sachs analyst Mark Delaney downgraded Seagate Technology (STX) to Sell from Neutral and lowered his price target for the shares to $44 from $50, representing 20% downside from current levels. While Seagate has improved its product offerings in the last few years, hard disk drives remain a cyclical industry, and one "facing secular challenges in many parts of the market," Delaney said. He believes Seagate's fundamentals will peak in the second half of 2018 and decline in 2019. RBC CUTS FOX TO SECTOR PERFORM ON VALUATION: RBC Capital analyst Steven Cahall downgraded 21st Century Fox (FOXA) to Sector Perform from Outperform, but raised his price target to $49 from $45. The analyst noted that the stock is now trading near its M&A price and that he does not see any competitive bids emerging. Cahall adds that while the company is "undervalued", he awaits the separation to re-evaluate his stance. MORGAN STANLEY DOWNGRADES SEMI INDUSTRY: Morgan Stanley analyst Joseph Moore said he has become less constructive on semiconductor stocks through the year and he now believes elevated inventory levels and stretched lead times leave "no margin for error." Given his view that any lead time adjustment or demand slowdown could drive a "meaningful correction," Moore has downgraded his semiconductor industry view to Cautious from In-Line. He favors connector companies, like Amphenol (APH) and TE Connectivity (TEL) over analog/MCU at this point in the cycle, due to lower risk around lead time issues, Moore said. He also has a "strong preference" for high margin and more defensive models, such as Analog Devices (ADI) over lower margin and commodity exposed ones, like Cypress Semiconductor (CY) and ON Semiconductor (ON), he said. Despite his more cautious view on the space, Moore kept Overweight ratings on Nvidia (NVDA), Xilinx (XLNX) and Ambarella (AMBA), citing his view that they should benefit from secular growth in the area of AI, data center, and autonomous. SOUTHERN COMPANY GETS MULTIPLE DOWNGRADES AFTER Q2 REPORT: Barclays analyst Eric Beaumont downgraded Southern Company (SO) to Equal Weight and lowered his price target for the shares to $48 from $51. Credit Suisse analyst Michael Weinstein downgraded Southern Company to Underperform from Neutral and lowered his price target on the shares to $43 from $46. Guggenheim analyst Shahriar Pourreza downgraded Southern Company to Neutral from Buy and lowered his price target on the stock to $47 from $50. Evercore ISI analyst Greg Gordon downgraded Southern Company to Underperform from In Line and lowered his price target on Southern shares to $46 from $46.75.
08/09/18
08/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Seagate (STX) downgraded to Sell from Neutral at Goldman Sachs by analyst Mark Delaney, who said that while Seagate has improved its product offerings in the last few years, hard disk drives remain a cyclical industry, and one "facing secular challenges in many parts of the market." 2. 21st Century Fox (FOXA) downgraded to Sector Perform from Outperform at RBC Capital by analyst Steven Cahall who noted that the stock is now trading near its M&A price and that he does not see any competitive bids emerging. 3. e.l.f. Beauty (ELF) downgraded to Hold from Buy at Jefferies by analyst Stephanie Wissink, who said she is disappointed with the company's "sales fall off," which she says "seems more systemic than previously assumed." e.l.f.'s profit advancement will reverse in the second half of the year amid stepped up brand investment. Shares were also downgraded to Underweight from Neutral at Piper Jaffray, who said she sees a "growing risk of shelf-space cuts into 2019" if underlying sales trends do not improve, at Citi to Neutral from Buy and at DA Davidson to Neutral from Buy. 4. Southern Company (SO) downgraded to Underperform from In Line at Evercore ISI by analyst Greg Gordon, who said he believes the shares are still not discounting enough risk after the company announced a $790M after-tax charge related to an increase in the cost estimate for constructing Vogtle Nuclear Plants 3 and 4. Shares were also downgraded to Underperform from Neutral at Credit Suisse, to Equal Weight from Overweight at Barclays and to Neutral from Buy at Guggenheim. 5. Schneider National (SNDR) downgraded to Underperform from Buy at BofA/Merrill by analyst Ken Hoexter, who cited "stretched" relative valuation. The analyst also downgraded Genesee & Wyoming (GWR) to Neutral from Buy, saying recent strength in shares has led to a premium multiple and sees minimal upside. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
American Society of Human Genetics to hold a conference »

ASHG Conference 2018 will…

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

CLBR

Caliburn International

$0.00

(0.00%)

18:27
10/19/18
10/19
18:27
10/19/18
18:27
Syndicate
Caliburn International files registration statement for proposed IPO »

Caliburn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

18:10
10/19/18
10/19
18:10
10/19/18
18:10
General news
Saudi Arabia says Kashoggi killed after fight broke out in consulate, CNBC says 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$21.51

0.41 (1.94%)

17:53
10/19/18
10/19
17:53
10/19/18
17:53
Syndicate
Breaking Syndicate news story on International Seaways »

International Seaways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$15.49

0.08 (0.52%)

17:48
10/19/18
10/19
17:48
10/19/18
17:48
Hot Stocks
Monmouth Real Estate acquires industrial building in New Jersey for $85.25M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:38
10/19/18
10/19
17:38
10/19/18
17:38
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:36
10/19/18
10/19
17:36
10/19/18
17:36
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

, LMT

Lockheed Martin

$328.22

0.21 (0.06%)

17:33
10/19/18
10/19
17:33
10/19/18
17:33
Periodicals
Trump to meet CEOs of Boeing, Lockheed Martin, General Dynamics, Reuters reports »

President Donald Trump…

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

LMT

Lockheed Martin

$328.22

0.21 (0.06%)

BA

Boeing

$356.28

-3 (-0.84%)

GD

General Dynamics

$190.43

-0.76 (-0.40%)

BAESY

BAE Systems

$0.00

(0.00%)

HON

Honeywell

$153.49

-1.73 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 30

    Oct

ISR

IsoRay

$0.50

0.0191 (3.98%)

17:25
10/19/18
10/19
17:25
10/19/18
17:25
Syndicate
Breaking Syndicate news story on IsoRay »

IsoRay files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHS

Neuberger Berman High Yield Strategies Fd

$10.55

-0.015 (-0.14%)

17:06
10/19/18
10/19
17:06
10/19/18
17:06
Hot Stocks
Breaking Hot Stocks news story on Neuberger Berman High Yield Strategies Fd »

Saba Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOC

Biocept

$2.27

-0.04 (-1.73%)

17:04
10/19/18
10/19
17:04
10/19/18
17:04
Syndicate
Breaking Syndicate news story on Biocept »

Biocept files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZO

AutoZone

$726.10

-4.09 (-0.56%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Hot Stocks
AutoZone founder Hyde will not stand for board re-election »

AutoZone announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

SACH

Sachem Capital

$4.33

0.02 (0.46%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Syndicate
Breaking Syndicate news story on Sachem Capital »

Sachem Capital files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

16:53
10/19/18
10/19
16:53
10/19/18
16:53
Conference/Events
Mirati Therapeutics to hold a conference call »

Dr. Charles Baum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SPNE

SeaSpine

$16.58

-0.54 (-3.15%)

16:47
10/19/18
10/19
16:47
10/19/18
16:47
Hot Stocks
Breaking Hot Stocks news story on SeaSpine »

First Light Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$8.76

-0.04 (-0.45%)

16:46
10/19/18
10/19
16:46
10/19/18
16:46
Conference/Events
Epizyme to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

16:40
10/19/18
10/19
16:40
10/19/18
16:40
General news
Breaking General news story on MSCI Italy Index, SPDR S&P 500 ETF Trust, S&P 500 »

Moody's cuts Italy…

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTC

Astrotech

$2.93

-0.02 (-0.68%)

16:39
10/19/18
10/19
16:39
10/19/18
16:39
Hot Stocks
Breaking Hot Stocks news story on Astrotech »

Winn Interests reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTMX

CytomX Therapeutics

$15.43

-1.075 (-6.52%)

16:38
10/19/18
10/19
16:38
10/19/18
16:38
Conference/Events
CytomX Therapeutics to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ICLK

iClick Interactive Asia

$3.41

(0.00%)

16:36
10/19/18
10/19
16:36
10/19/18
16:36
Hot Stocks
Breaking Hot Stocks news story on iClick Interactive Asia »

LIM Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.